


Data Sheet

Product Information

Catalog Number	BP15232
Product Name	Veliflapon
Description	Veliflapon is an orally active and selective inhibitor of 5-lipoxygenase activating protein (FLAP). Veliflapon inhibits the synthesis of the leukotrienes B4 and C4.
In vitro	Veliflapon inhibits the synthesis of LTB4 in A23187-stimulated leukocytes from rats, mice and humans with IC50s of 0.026, 0.039 and 0.22 μ M, respectively as well as the formation of LTC4 with IC50 of 0.021 μ M in mouse peritoneal macrophages stimulated with opsonized zymosan.
In vivo	Atherogenesis inhibited by Veliflapon (DG-031; diet; 18.8 mg/kg/day for 16 weeks). In the arachidonic acid-induced mouse ear inflammation test, Veliflapon after topical (18 μ g/ear) and oral (48.7 mg/kg) administration has antiedematous effects . Veliflapon is potent (11.8 and 6.7 mg/kg p.o. at 1 and 5 hours, respectively) and has a long duration of action (ED40 of 16 hours, 70 mg/kg p.o.) in the rat whole blood ex vivo leukotriene B4 inhibition assay.
Synonyms	BAY X 1005, DG-031
CAS No.	128253-31-6
Chemical Formula	C23H23NO3
Molecular Weight	361.441
Solubility	
Storage	Powder: -20°C for 2 years In solvent: -80°C for 1 year

Chemical Structure
OR
Tested Image



Purdue Bioscience Inc.

750 50th St, Brooklyn, NY 11220, USA

<https://www.purduebio.com>

1-877.618.7311

info@purduebio.com

v2 Revision on 12/28/2022